Skip to content


Research Summary

VIC’s immuno-oncology program focuses on hard to treat solid tumors (mesothelioma, ovarian cancer) and enhanced cancer risk in chronic viral infections (HIV & HPV).

The long-term objective of the program is improved therapeutic outcomes based on modulation of the anti-tumor immune response.

Current active research areas include:

  • Novel molecule-based and cell-based immunotherapies for the treatment of solid tumors
  • Understanding the immunosuppressive tumor microenvironment (TME) and new strategies for reshaping the TME
  • Mechanism(s) by which HIV-1 infection promotes the development or progression of tumors

Immuno-oncology Pipeline

1 : Initial R&D

2 : Preclinical Efficacy

3 : Preclinical Safety

4 : Initial Human Studies

Highlighted Publications

Cancer Immunol Res. 2018 May;6(5):539-551 PMID: 29511032
Li B, Zeng Y, Reeves PM, Ran C, Liu Q, Qu X, Liang Y, Liu Z, Yuan J, Leblanc PR, Ye Z, Sluder AE, Gelfand JA, Brauns TA, Chen H, Poznansky MC.

Expert Rev Vaccines. 2015 Mar;14(3):435-46. doi: 10.1586/14760584.2015.979797. Epub 2014 Dec 13. Review. PMID: 25496347
Brauns T, Leblanc P, Gelfand JA, Poznansky MC.

Oncotarget. 2019 Jul 8;10(43):4479-4491. PMID:31320999
Zeng Y, Li B, Li T, Liu W, Ran C, Penson RT, Poznansky MC, Du Y, Chen H

explore these labs for more info